. . . . . . . "[Overall, the prevalence of KRAS exon 2 was 36.8%, and it was lower in liver metastases (N?=?138/490; 28.2%) in comparison with primary tumors (N?=?442/1086; 40.7%), lung metastases (16/32; 50%), or other metastatic sites (15/51; 29.4%; P?<?0.0001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:14:11+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .